Cancer incidence has increased in the last decades. Meanwhile, new and costly intravenous chemotherapy (CT) drugs are added to current treatment options. Cost of chemotherapy is not restricted to drugs themselves, and some of the equipment used for infusion can impact the final value. CT can be administered on simple IV lines although some schemes require the use of pump infusion sets (PIS) which can be PVC free or photo-protective depending on the drug. Nonetheless, several cancer centers in Brazil adopt CT pump infusion as a rule, despite manufacturers instructions. We aim to assess the added cost of unnecessary PIS use during CT infusion.
METHODS:
In this cost-minimization study we compared 2 scenarios: use of PIS according to manufacturers' recommendations or as a indiscriminately for all CT. Chemotherapy treatments for breast cancer (AC-T, AC-TH, TAC, FAC, CMF and FEC100), lung cancer (carboplatin/ with and without bevacizumab, vinorelbine/cisplatin, cisplatin/paclitaxel and pemetrexed/ cisplatin) and colon cancer (fluorouracil/leucovorin, FOLFIRI, FOLFOX, cetuximab/irinotecan) were listed from the Brazilian Society of Clinical Oncology (SBOC) manual. Minimum, mean and maximal costs for drugs and equipment were retrieved from the official price list (SIMPRO), daily cost of infusion and increment in cost were also calculated in Brazilian Reais (R$).
RESULTS:
Fifteen CT combinations were evaluated (6 for breast, 5 for colon and 4 for lung cancer). For breast cancer, the mean incremental cost per day of infusion with PIS varied from R$ 994.35 to R$ 1,839.54, depending on the chemotherapy scheme used. For lung cancer these values varied from R$ 356.34 to R$ 1,201.53 and for colon cancer treatment the incremental cost was R$ 1,226.36.
CONCLUSION:
Although medications are the main source of expense in cancer treatment, unnecessary use of PIS can add considerable costs to chemotherapy and correct use according to manufacturer recommendation should be reinforced. Evidências -Kantar Health, Campinas, Brazil Cancer is an important cause of hospitalization, morbidity and mortality worldwide. Healthcare expenditure is increasing globally. According to data published by the Brazilian National Health Agency (ANS), medical and hospital revenues in the first semester of 2014 were 14.9% higher than in the same period of 2013, while expenses were 15.6% higher.
5
Chemotherapy (CT) costs are a constant source of concern for healthcare systems managers, since new drugs have increasingly higher prices.
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Nevertheless, CT costs are not limited to the cost of drugs, per se, as several other relatively inexpensive items must be added, such as needles, syringes, infusions sets, etc.
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Infusion sets, defined as clear, flexible, plastic tubes used for intravenous infusions, are frequent items in the list of expenses of any oncology treatment unit. Some medications must be infused through special equipment (PVC free sets or tubes with photo-protection), while some drugs must be infused in a time-controlled fashion requiring the use of infusion pumps.
Despite being necessary to only a limited group of drugs, it is common practice in Brazilian oncology centers to use pump infusion sets (PIS) to administer any CT medication. Although these sets are not high-cost equipment, excessive use can impact the final cost of treatment for payers.
Our goal was to compare the use of PIS according to manufacturer recommendations versus indiscriminate use in oncology centers in Brazil and perform a cost-minimization analysis (CMA).
INTRODUCTION
• • • • • •
RESULTS
We evaluated 15 chemotherapy schemes: 6 for breast cancer, 5 for colon and 4 for lung cancer. Some drugs are commonly used in more than one scheme and for more than one disease.
Detailed results are depicted on Tables 1, 2 and 3. • • The incremental costs secondary to the indiscriminate use of PIS are relevant in absolute terms and should be considered when analyzing oncologic treatments.
The price of infusion sets is widely variable, even when one considers equipment within the same characteristics.
We found that the incremental costs due to the indiscriminate use of PIS in the most frequently used chemotherapy treatments of breast, lung and colon cancer varied from R$ 356.34 to R$ 1,839.04.
The incremental costs due to the indiscriminate use of PIS can be considered unnecessary, since not all drugs must be infused in a precisely, time-controlled manner. When manufacturer's instructions are followed it is possible to reduce the waste of resources in cancer treatments. This payment model however, may incite service providers to use high-cost materials in order to demand a higher reimbursement price from health insurance companies (HIC). The scenario becomes even more complicated since oftentimes most HIC already pay full-price for drugs and equipment, while providers are able to buy them at discounted prices. This gap between buying and reimbursing prices may lead providers to choose items with the largest difference to achieve greater profit.
Thus, a conflict of interests emerges, turning the choice of infusion sets from clinical need to profit margin. Also, the preference for PIS may be based on attempts to reduce the workload of nurses, who can rely on the equipment's alarms and mechanisms, being thus free to care for other patients.
HIC in Brazil must be attentive to the issue discussed here, implement control methods and find the best reimbursement agreement to avoid waste during chemotherapy treatments.
Although PIS may facilitate the work of nurses, chemotherapy infusions can be easily monitored by dripping rate and the level of content on the vial. The panelist selected the following schemes:
All schemes with the respective drugs and the equipment necessary to perform the infusions were input on Excel spreadsheets. Special infusion sets required for specific drugs (photo-protection, PVC free and DEHP free) were also considered.
Minimum, maximum and mean costs as well as daily cost of infusion and incremental costs were all calculated based on the official list of prices known as SIMPRO and are listed in Brazilian Reais (R$) with an exchange rate of 1US$ to 3.2R$. 
